The PPARα Agonist Fenofibrate Attenuates Disruption of Dopamine Function in a Maternal Immune Activation Rat Model of Schizophrenia
Overview
Pharmacology
Authors
Affiliations
Aims: Prenatal maternal immune activation (MIA) is associated with a risk to develop schizophrenia and affects dopamine systems in the ventral tegmental area (VTA), key region in the neurobiology of psychoses. Considering the well-described sex differences in schizophrenia, we investigated whether sex affects MIA impact on dopamine system and on schizophrenia-related behavioral phenotype. Furthermore, considering peroxisome proliferator-activated receptor-α (PPARα) expression in the CNS as well as its anti-inflammatory and neuroprotective properties, we tested if PPARα activation by prenatal treatment with a clinically available fibrate (fenofibrate) may mitigate MIA-related effects.
Methods: We induced MIA in rat dams with polyriboinosinic-polyribocytidylic acid (Poly I:C) and assessed prepulse inhibition and dopamine neuron activity in the VTA by means of electrophysiological recordings in male and female preweaned and adult offspring.
Results: Poly I:C-treated males displayed prepulse inhibition deficits, reduced number and firing rate of VTA dopamine neurons, and paired-pulse facilitation of inhibitory and excitatory synapses. Prenatal fenofibrate administration attenuated detrimental effects induced by MIA on both the schizophrenia-like behavioral phenotype and dopamine transmission in male offspring.
Conclusion: Our study confirms previous evidence that females are less susceptible to MIA and highlights PPARα as a potential target for treatments in schizophrenia.
Sonego A, Prado D, Uliana D, Cunha T, Grace A, Resstel L Eur Neuropsychopharmacol. 2024; 89:28-40.
PMID: 39332147 PMC: 11606766. DOI: 10.1016/j.euroneuro.2024.09.001.
Zulinska S, Strosznajder A, Strosznajder J Int J Mol Sci. 2024; 25(13).
PMID: 39000217 PMC: 11241121. DOI: 10.3390/ijms25137106.
Perez-Palomar B, Erdozain A, Erkizia-Santamaria I, Ortega J, Meana J J Neuroimmune Pharmacol. 2023; 18(3):348-365.
PMID: 37208550 PMC: 10577104. DOI: 10.1007/s11481-023-10070-1.
Adraoui F, Douw L, Martens G, Maas D Int J Mol Sci. 2023; 24(9).
PMID: 37175387 PMC: 10177877. DOI: 10.3390/ijms24097680.
CTNNB1 in neurodevelopmental disorders.
Zhuang W, Ye T, Wang W, Song W, Tan T Front Psychiatry. 2023; 14:1143328.
PMID: 37009120 PMC: 10061110. DOI: 10.3389/fpsyt.2023.1143328.